PDF下载 ( 2049 KB)
我国部分地区慢性HBV感染者HDV感染情况调查
DOI: 10.3969/j.issn.1001-5256.2023.04.009
利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明：刘玉梅完成实验和数据分析，撰写论文；郭小平、张慧敏、白洪霞、王春梅、任姗、蒋永芳、杨胜、彭锋、王晓忠、于雷、廖柏明、宁玲、何英利、杨霞、黄亮参与收集样本和临床数据；刘学恩、庄辉负责课题设计，指导撰写文章并最后定稿。
An investigation of hepatitis D virus infection among patients with chronic hepatitis B virus infection in some regions of China
-
摘要:
目的 了解目前我国部分地区慢性HBV感染者丁型肝炎病毒(HDV) 感染流行情况。 方法 2021年3月—2022年6月从全国10个省市自治区收集3 131例慢性HBV感染者血清，用抗-HDV IgG酶联免疫试剂检测全部血清标本。对抗-HDV IgG阳性标本用巢式逆转录聚合酶链式反应(nRT-PCR) 法检测HDV RNA。对HDV RNA阳性标本的nRT-PCR扩增产物测序后进行序列分析，确定HDV基因型。分析抗-HDV IgG阳性患者的临床特征。计量资料两组间比较采用Mann-Whitney U秩和检验。计数资料两组间比较采用χ2检验或Fisher精确检验。 结果 3 131例慢性HBV感染者的抗-HDV IgG阳性率为0.70%(22/3 131)，内蒙古自治区、新疆维吾尔自治区、北京市和湖南省慢性HBV感染者的抗-HDV IgG阳性率分别为1.81%(16/886)、0.88%(2/226)、0.28%(2/708) 和1.00%(2/200)，其中内蒙古自治区慢性HBV感染者抗-HDV IgG阳性率显著高于北京市(P=0.004)，其余地区间比较差异均无统计学意义(P值均＞0.05)。对内蒙古自治区慢性HBV感染者临床特征分析发现，抗-HDV IgG阳性组蒙古族患者(P=0.001)、ALT异常患者(P=0.007) 和抗病毒治疗患者(P=0.029) 的比例显著高于抗-HDV IgG阴性组，而中位HBV DNA水平明显较低(P=0.030)。共检出19例HDV RNA阳性标本，均为HDV基因1型。 结论 我国不同地区HDV流行率差异较大，内蒙古自治区慢性HBV感染者中HDV流行率较高。我国北方部分省市的HDV流行基因型主要为1型。 Abstract:Objective To investigate the prevalence of hepatitis D virus (HDV) infection among patients with chronic hepatitis B virus (HBV) infection in some regions of China. Methods Serum samples were collected from 3 131 patients with chronic HBV infection in 10 provinces, cities, and autonomous regions of China from March 2021 to June 2022, and anti-HDV IgG ELISA was used for the detection of all serum samples. Nested reverse transcription-polymerase chain reaction (nRT-PCR) was used to detect HDV RNA in anti-HDV IgG-positive samples, and the nRT-PCR amplification products of HDV RNA-positive samples were sequenced and analyzed to determine HDV genotype. The clinical features of anti-HDV IgG-positive patients were analyzed. The Mann-Whitney U rank sum test was used for comparison of continuous data between two groups, and the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups. Results The positive rate of anti-HDV IgG in the 3 131 patients with chronic HBV infection was 0.70% (22/3 131), and that in the patients with chronic HBV infection in Inner Mongolia Autonomous Region, Xinjiang Uygur Autonomous Region, Beijing, and Hunan Province was 1.81% (16/886), 0.88% (2/226), 0.28% (2/708), and 1.00% (2/200), respectively; the patients with chronic HBV infection in Inner Mongolia Autonomous Region had a significantly higher positive rate of anti-HDV IgG than those in Beijing (P=0.004), and there was no significant difference between the other regions (P > 0.05). Clinical features of the patients with chronic HBV infection in Inner Mongolia Autonomous Region showed that compared with the anti-HDV IgG-negative group, the anti-HDV IgG-positive group had a significantly higher proportion of patients with Mongol nationality (P=0.001), abnormal alanine aminotransferase (P=0.007), or antiviral treatment (P=0.029), as well as a significantly lower median HBV DNA level (P=0.030). A total of 19 HDV RNA-positive samples were identified, all of which had HDV genotype 1. Conclusion The prevalence rate of HDV varies greatly across different regions of China, with a higher prevalence rate of HDV in patients with chronic HBV infection from Inner Mongolia Autonomous Region. HDV genotype 1 is the predominant genotype in some provinces and cities of northern China. -
Key words:
- Hepatitis B Virus /
- Hepatitis Delta Virus /
- Anti-HDV IgG /
- Genotype
-
图 1 我国部分地区慢性HBV感染者HDV感染流行率
Figure 1. Prevalence rates of HDV infection among patients with chronic HBV infection in some areas of China
图 2 内蒙古地区抗-HDV IgG阳性和阴性慢性HBV感染者临床特征比较
Figure 2. Clinical characteristics of anti-HDV IgG positive and negative patients with chronic HBV infection in Inner Mongolia
表 1 内蒙古地区有明确诊断的720例各类慢性HBV感染者抗-HDV IgG阳性率
Table 1. The positive rate of anti-HDV IgG in 720 patients with chronic HBV infection with definite diagnosis in Inner Mongolia
临床诊断 例数 抗-HDV IgG阳性
[例(%)]HBsAg携带者 160 1(0.63) 慢性乙型肝炎 525 9(1.71) 乙型肝炎肝硬化 33 2(6.06) 肝癌 2 0(0.00) 合计 720 12(1.67) 
下载: 导出CSV
表 2 抗-HDV IgG阳性和阴性慢性HBV感染者临床特征
Table 2. Clinical characteristics of anti-HDV IgG positive and negative patients with chronic HBV infection
临床特征 慢性HBV感染者 抗-HDV IgG阴性 抗-HDV IgG阳性 统计值 P值 男/女(例) 1 842/1 160
(n=3 002)1 830/1 150
(n=2 980)12/10
(n=22)χ2=0.434 0.510 年龄(岁) 47.00(37.00~56.00)
(n=2 996)47.00(37.00~56.00)
(n=2 974)46.00(40.75~54.00)
(n=22)Z=0.382 0.702 民族(汉/蒙古族/其他, 例) 2 037/134/135
(n=2 306)2 027/125/135
(n=2 287)10/9/0
(n=19)χ2=27.535 ＜0.001 临床诊断(慢性乙型肝炎合并肝硬化/肝癌, 例) 470/214
(n=2 826)467/214
(n=2 809)3/0
(n=17)χ2=1.203 0.719 抗病毒治疗史(有/无, 例) 1 212/490
(n=1 702)1 202/489
(n=1 691)10/1
(n=11)0.194 HBV DNA(log10 IU/mL) 2.00(1.30~3.43)
(n=2 762)2.00(1.30~3.43)
(n=2 740)1.48(1.48~2.95)
(n=22)Z=0.821 0.412 HBsAg阳性[例(%)] 2 741(97.79)
(n=2 803)2 721(97.77)
(n=2 783)20(100.00)
(n=20)＞0.05 HBeAg阳性[例(%)] 927(37.62)
(n=2 464)921(37.64)
(n=2 447)6(35.29)
(n=17)χ2=0.040 0.842 抗-HBc阳性[例(%)] 2 196(83.69)
(n=2 624)2 178(83.64)
(n=2 604)18(90.00)
(n=20)0.759 抗HCV阳性[例(%)] 19(1.03)
(n=1 842)19(1.04)
(n=1 826)0(0.00)
(n=16)＞0.05 抗HIV阳性[例(%)] 9(0.50)
(n=1 797)9(0.51)
(n=1 782)0(0.00)
(n=15)＞0.05 ALT(U/L) 25.08(17.00~39.20)
(n=2 851)25.00(17.00~39.00)
(n=2 831)26.04(14.98~50.63)
(n=20)Z=0.335 0.738 ALT＞40 U/L[例(%)] 686(24.06)
(n=2 851)678(23.95)
(n=2 831)8(40.00)
(n=20)0.113 AST(U/L) 26.00(20.00~38.00)
(n=2 838)26.00(20.00~38.00)
(n=2 818)24.69(20.83~36.50)
(n=20)Z=0.206 0.837 AST＞40 U/L[例(%)] 623(21.95)
(n=2 838)620(22.00)
(n=2 818)3(15.00)
(n=20)0.593 ALP(U/L) 78.00(63.0~99.00)
(n=2 573)78.00(63.00~99.00)
(n=2 555)75.05(64.00~94.58)
(n=18)Z=0.342 0.733 GGT(U/L) 26.00(16.00~44.00)
(n=2 577)26.00(16.00~44.00)
(n=2 559)24.63(12.75~50.50)
(n=18)Z=0.161 0.872 PLT(×109/L) 183.00(123.00~231.80)
(n=2 523)182.50(123.53~231.80)
(n=2 506)190.00(92.50~237.00)
(n=17)Z=0.348 0.728 TBil(μmol/L) 16.30(12.16~23.20)
(n=2 833)16.30(12.20~23.20)
(n=2 815)12.50(10.18~19.35)
(n=18)Z=1.753 0.080 AFP(ng/mL) 2.85(1.92~4.88)
(n=2 380)2.86(1.92 ~4.90)
(n=2 368)2.24(1.76 ~2.79)
(n=12)Z=1.959 0.050 注：n表示有数据患者的例数。
下载: 导出CSV
-
[1] RIZZETTO M. The adventure of delta[J]. Liver Int, 2016, 36(Suppl 1): 135-140. DOI: 10.1111/liv.13018. [2] YAN H, ZHONG G, XU G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife, 2012, 1: e00049. DOI: 10.7554/eLife.00049. [3] MIAO Z, XIE Z, REN L, et al. Hepatitis D: advances and challenges[J]. Chin Med J (Engl), 2022, 135(7): 767-773. DOI: 10.1097/CM9.0000000000002011. [4] DAI ZC, QI GM. National sero-epidemiological survey of viral hepatitis (volume Ⅰ)1992-1995[M]. Beijing: Scientific and Technical Documents Publishing House, 1997.戴志澄, 祁国明. 中国病毒性肝炎血清流行病学调查(上卷)1992-1995[M]. 北京: 科学技术文献出版社, 1997. [5] ZHAN MY, LIU SL, YI YJ, et al. Molecular biology and sero-epidemiology of hepatitis D virus in China[J]. Bulletin Med Res, 1996, 25(10): 9-11. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYZ199908004.htm詹美云, 刘善虑, 易炎杰, 等. 我国丁型肝炎病毒分子生物学和血清流行病学研究[J]. 医学研究通讯, 1996, 25(10): 9-11. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYZ199908004.htm [6] STOCKDALE AJ, KREUELS B, HENRION MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis[J]. J Hepatol, 2020, 73(3): 523-532. DOI: 10.1016/j.jhep.2020.04.008. [7] CHEN HY, SHEN DT, JI DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis[J]. Gut, 2019, 68(3): 512-521. DOI: 10.1136/gutjnl-2018-316601. [8] KOH C, HELLER T, GLENN JS. Pathogenesis of and new therapies for hepatitis D[J]. Gastroenterology, 2019, 156(2): 461-476. DOI: 10.1053/j.gastro.2018.09.058. [9] FARCI P, NIRO GA. Clinical features of hepatitis D[J]. Semin Liver Dis, 2012, 32(3): 228-236. DOI: 10.1055/s-0032-1323628. [10] NIRO GA, FERRO A, CICERCHIA F, et al. Hepatitis delta virus: from infection to new therapeutic strategies[J]. World J Gastroenterol, 2021, 27(24): 3530-3542. DOI: 10.3748/wjg.v27.i24.3530. [11] MIAO Z, ZHANG S, OU X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection[J]. J Infect Dis, 2020, 221(10): 1677-1687. DOI: 10.1093/infdis/jiz633. [12] LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469. [13] LIU HM, TAN ZX, YANG J, et al. Prevalence and clinical characteristics of hepatitis D in southwest of China[J]. Chin J Exp Clin Virol, 2022, 36(1): 85-91. DOI: 10.3760/cma.j.cn112866-20210611-00096.刘慧敏, 谭朝霞, 杨京, 等. 中国西南地区丁型肝炎的流行状况与临床特征分析[J]. 中华实验和临床病毒学杂志, 2022, 36(1): 85-91. DOI: 10.3760/cma.j.cn112866-20210611-00096. [14] Chinese Society of Infectious Disesses, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. [15] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. [16] PERVEEN S, NASIR MI, SHAHID SM, et al. Phylogenetic analysis of HDV isolates from HBsAg positive patients in Karachi, Pakistan[J]. Virol J, 2012, 9: 162. DOI: 10.1186/1743-422X-9-162. [17] LIU YM, BAI HX, MA YH, et al. Evaluation of four anti-HDV IgG detection reagents for hepatitis D virus[J]. Chin J Viral Dis, 2022, 12(3): 170-174. DOI: 10.16505/j.2095-0136.2022.0024.刘玉梅, 白洪霞, 马亚红, 等. 4种丁型肝炎病毒IgG抗体检测试剂的评价[J]. 中国病毒病杂志, 2022, 12(3): 170-174. DOI: 10.16505/j.2095-0136.2022.0024. [18] BOTELHO-SOUZA LF, VASCONCELOS MPA, DOS SANTOS AO, et al. Hepatitis delta: virological and clinical aspects[J]. Virol J, 2017, 14(1): 177. DOI: 10.1186/s12985-017-0845-y. [19] SAGNELLI C, PISATURO M, CURATOLO C, et al. Hepatitis B virus/hepatitis D virus epidemiology: changes over time and possible future influence of the SARS-CoV-2 pandemic[J]. World J Gastroenterol, 2021, 27(42): 7271-7284. DOI: 10.3748/wjg.v27.i42.7271. [20] RIZZETTO M, HAMID S, NEGRO F. The changing context of hepatitis D[J]. J Hepatol, 2021, 74(5): 1200-1211. DOI: 10.1016/j.jhep.2021.01.014. [21] EL BOUZIDI K, ELAMIN W, KRANZER K, et al. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London[J]. J Clin Virol, 2015, 66: 33-37. DOI: 10.1016/j.jcv.2015.02.011. [22] SAFAIE P, RAZEGHI S, ROUSTER SD, et al. Hepatitis D diagnostics: utilization and testing in the United States[J]. Virus Res, 2018, 250: 114-117. DOI: 10.1016/j.virusres.2018.03.013. [23] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021. [24] TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800. [25] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4. [26] LIU YM, LIU XE, ZHUANG H. Advances in development of new anti-HDV drugs[J]. Chin J Viral Dis, 2021, 11(6): 414-419. DOI: 10.16505/j.2095-0136.2021.0054.刘玉梅, 刘学恩, 庄辉. 丁型肝炎抗病毒新药研究进展[J]. 中国病毒病杂志, 2021, 11(6): 414-419. DOI: 10.16505/j.2095-0136.2021.0054. [27] ROGGENBACH I, CHI X, LEMPP FA, et al. HDV seroprevalence in HBsAg-positive patients in China occurs in hotspots and is not associated with HCV mono-infection[J]. Viruses, 2021, 13(9): 1799. DOI: 10.3390/v13091799. [28] WANG Y. Survey of HDV infection and molecular characterization of HDV, HBV and HIV-1 among chronic hepatitis B patients in China[D]. Beijing: Chinese Center for Disease Control and Prevention, 2018.王彦. 我国丁型肝炎病毒感染情况调查和病毒分子特性研究[D]. 北京: 中国疾病预防控制中心, 2018. [29] JANG TY, WEI YJ, YEH ML, et al. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues[J]. J Formos Med Assoc, 2021, 120(1 Pt 2): 303-310. DOI: 10.1016/j.jfma.2020.10.002. [30] GU XH, LI QF, WANG YM. Clinical characteristics of the patients with hepatitis B combining hepatitis D infection[J]. Chin J Hepatol, 2001, 9(1): 34-36. DOI: 10.3760/j.issn:1007-3418.2001.01.011.顾小红, 李奇芬, 王宇明. 伴HDV感染的乙型肝炎患者的临床特征[J]. 中华肝脏病杂志, 2001, 9(1): 34-36. DOI: 10.3760/j.issn:1007-3418.2001.01.011. [31] WU S, ZHANG Y, TANG Y, et al. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China[J]. BMC Infect Dis, 2020, 20(1): 565. DOI: 10.1186/s12879-020-05275-1. [32] LIAO B, ZHANG F, LIN S, et al. Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China[J]. PLoS One, 2014, 9(12): e115888. DOI: 10.1371/journal.pone.0115888. [33] LEE AU, LEE C. Hepatitis D review: challenges for the resource-poor setting[J]. Viruses, 2021, 13(10): 1912. DOI: 10.3390/v13101912. [34] FARCI P, ANNA NIRO G. Current and future management of chronic hepatitis D[J]. Gastroenterol Hepatol (N Y), 2018, 14(6): 342-351. [35] RIZZETTO M, HAMID S. The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal[J]. Liver Int, 2021, 41(1): 16-19. DOI: 10.1111/liv.14729. -
本文二维码
图(2) / 表(2)
计量
- 文章访问数: 514
- HTML全文浏览量: 127
- PDF下载量: 110
- 被引次数: 0
